Published in final edited form as:

Life Sci. 2010 September 25; 87(13-14): 391–400. doi:10.1016/j.lfs.2010.07.010.

Extracellular Matrix Roles During Cardiac Repair

Claude Jourdan-LeSaux¹, Jianhua Zhang¹, and Merry L. Lindsey¹

¹Division of Cardiology, Department of Medicine, The University of Texas Health Science Center at San Antonio

Abstract

The cardiac extracellular matrix (ECM) provides a platform for cells to maintain structure and function, which in turn maintains tissue function. In response to injury, the ECM undergoes remodeling that involves synthesis, incorporation, and degradation of matrix proteins, with the net outcome determined by the balance of these processes. The major goals of this review are a) to serve as an initial resource for students and investigators new to the cardiac ECM remodeling field, and b) to highlight a few of the key exciting avenues and methodologies that have recently been explored. While we focus on cardiac injury and responses of the left ventricle (LV), the mechanisms reviewed here have pathways in common with other wound healing models.

Keywords

extracellular matrix; left ventricular remodeling; matrix metalloproteinases; inflammation; fibrosis; review

Introduction

The extracellular matrix (ECM) is the intricate network that fills the space between cells. Composed of proteins locally secreted and organized, ECM includes fibrillar and non-fibrillar proteins that serve primary and accessory roles. In connective tissue (e.g. cartilage, bone, tendons, skin), ECM is more abundant than cells. In the heart under normal physiological conditions, cardiac myocytes occupy the highest volume of space and ECM is less abundant than cells. ECM is very diverse and adaptable both among different tissue types and in terms of composition and quality within the same tissue under different conditions. ECM proteins known to be expressed in myocardial tissue following injury are listed in table 1. We have known for almost 40 years that ECM is not an inert scaffold, but rather serves critical signaling functions. (Meier and Hay 1975) ECM provides mechanical support to the heart that allows it to pump blood; ECM allows cell-cell signaling by providing a pathway for signals to traverse; and ECM regulates cell functions including proliferation, adhesion, and migration (Holmes, et al. 2005).

Under normal physiological conditions, the ECM in the left ventricle (LV) is sufficient to maintain architecture and preserve tissue function. Following injury, such as myocardial

© 2010 Elsevier Inc. All rights reserved

Address for Correspondence: Merry L. Lindsey, Ph.D. Cardiology Division, Department of Medicine The University of Texas Health Science Center at San Antonio 7703 Floyd Curl Drive, Mail Code 7872 San Antonio, TX 78229-3900 (phone) 210-567-4673 (fax) 210-567-6960 lindseym@uthscsa.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

infarction (MI), cardiac myocytes undergo cell necrosis and are replaced by an infarct scar that is primarily composed of ECM. We will use MI as a prototypic cardiac injury model in this review, because MI is a highly prevalent cardiac disease (1.5 million Americans each year are diagnosed with MI) (Kolansky 2009) and because the LV reaction to MI follows a classic wound healing response (Frantz, et al. 2009). Below, we highlight 7 major concepts about cardiac ECM remodeling and discuss major directions that the field is taking to answer remaining issues.

1. Inflammation is a key component in the cardiac ECM response

MI, commonly referred to as a heart attack, occurs when an atherosclerotic artery in the coronary vasculature becomes totally occluded, which cuts off the oxygen supply to the downstream myocardium. When ischemia is of sufficient duration (>60 min), cardiac myocytes undergo necrosis leading to the upregulation of the complement cascade, stimulation of the toll-like receptor pathway, and increased reactive oxygen species (Frangogiannis and Entman 1997, Frangogiannis, et al. 2002, Oyama, et al. 2004, Riad, et al. 2008, Rossen, et al. 1988, Stutz, et al. 2009). These three components induce NF- κ B signaling to upregulate chemokines and cytokines, which in turn sequentially recruit platelets, neutrophils and mononuclear cells. This in turn leads to an inflammatory response involving the amplified upregulation of cytokines, chemokines, and growth factors (Table 2) (Deten, et al. 2002, Irwin, et al. 1999). Levels of these cytokines influence remodeling by coordinating the inflammatory response (Irwin, et al. 1999, Ono, et al. 1998).

Neutrophils are the first leukocyte responders, and neutrophil influx in the absence of reperfusion peaks at 24 h post-MI. Beginning around day 3 post-MI, macrophages infiltrate to engulf necrotic myocytes and apoptotic neutrophils (Lambert, et al. 2008). Inflammatory cells release remodeling enzymes that degrade the ECM to help to remove necrotic cells but also leave the myocardium structurally weak. Macrophages also activate fibroblasts, in part by releasing transforming growth factor β_1 (TGF β_1) (Sun, et al. 2000). TGF β_1 potently suppresses the inflammatory response and stimulates ECM synthesis in cardiac fibroblasts by activating the conversion of fibroblasts to myofibroblasts (Wynn 2008). Angiogenesis is also stimulated by activating endothelial cells to promote vascularization of the granulation tissue (Banerjee, et al. 2009, Bowers, et al. 2010, Dobaczewski and Frangogiannis 2009, Frangogiannis 2008, Hori and Nishida 2009). If all goes well, the healing infarct will mature, fibroblasts will undergo apoptosis and be removed, and the inflammatory response will resolve. The LV response to MI shares many common features with other wound healing models. For example, inflammation, fibrotic, and angiogenic responses are in common to MI, skin, and lung responses to injury (Hogg and Timens 2009, Palatinus, et al. 2010, Wilson and Wynn 2009).

When the coronary artery is re-opened (reperfusion), the main effects to the inflammatory response are that inflammatory cell infiltration is accelerated and amplified and all types of leukocytes enter the tissue at the same time (Frangogiannis 2008, Herskowitz, et al. 1995). For example, leukocytes have been measured in the cardiac lymph drainage as early as 15 min post-reperfusion (Lindsey, et al. 2001). In the canine MI model of reperfusion, neutrophil influx is 80% increased compared to permanent occlusion (Chatelain, et al. 1987). In comparing permanent occlusion to reperfusion, the Entman laboratory showed that for mice, when infarct sizes were similar (30% at 24 hours), permanent occlusion resulted in more infarct expansion (Michael, et al. 1999). Mortality rate in the reperfused group was 30% lower than total occlusion at 28 day post-MI, and left ventricular ejection and filling velocities return to control levels after 2 weeks and are sustained with reperfusion (Michael, et al. 1999, Vandervelde, et al. 2006). Reperfusion, therefore, yields a functionally improved LV compared to the non-reperfused LV.

2. Fibroblast activation is a prerequisite for cardiac repair

During the MI response, cardiac fibroblasts are recruited from resident cells and from a pool of circulating fibrocytes and are stimulated to undergo phenotypic modulation to become myofibroblasts (Figure 1) (Brown, et al. 2005, Camelliti, et al. 2005, Espira and Michael 2009, Porter and Turner 2009, Porter, et al. 2004, Turner, et al. 2009, Turner, et al. 2007, Turner, et al. 2004). In between the fibroblast and myofibroblast stage, there is an intermediary cell known as the protomyofibroblast (Desmouliere, et al. 2005). While not much is presently known about the conversion from a fibroblast to protomyofibroblast, the conversion to a myofibroblast has been directly attributed to the production of TGF β ₁ and the local presence of the cellular fibronectin splice variant ED-A (Serini, et al. 1998, Serini and Gabbiani 1999).

Myofibroblasts are a critical component of the repair process following myocardial injury (Espira and Michael 2009). Indeed, these cells ensure adequate scar formation required to maintain the structural integrity of the LV. In addition, the presence of myofibroblasts in the site of injury reduces infarct expansion due to increased contractile properties of myofibroblasts (Hinz, et al. 2001, Hinz, et al. 2001, Hinz, et al. 2007). Similar to the inflammatory response, the fibroblast response post-MI is similar to what is seen in the skin during wound healing. The Gourdie lab has written a comprehensive review on how we can translate lessons from the skin, particularly related to fibroblast function, to the post-MI setting (Palatinus, et al. 2010).

During the repair phase, factors that both diminish or enhance fibroblast activation are associated with increased incidences of post-MI rupture, indicating that scar formation follows a U-shaped curve response. For example, periostin gene deletion is associated with increased rupture rates and decreased fibroblast activation markers in post-MI mice (Shimazaki, et al. 2008). At the same time, the Blankesteyn lab has shown that mouse strains with high rupture rates (129SV and C57/BL6) also have the highest myofibroblast numbers at day 14 compared with more rupture resistant strains (FVB, Swiss, and Balb/c) (van den Borne, et al. 2009). Further, anti-TGF β ₁ treatment before or after MI in mice paradoxically increases both mortality and LV remodeling (Frantz, et al. 2008, Ikeuchi, et al. 2004). This effect was accompanied by decreased levels of early collagen deposition and decreased matrix metalloproteinase-9 (MMP-9) levels. The above discussion on rupture has focused on the mouse model of permanent coronary artery occlusion, because rupture is not a common complication in other animal models of MI and rupture is not a frequent occurrence in the presence of reperfusion. While fibroblast activation, therefore, has both negative and positive effects on remodeling, therapeutic strategies that temper fibroblast activation to influence negative aspects need to also take into account effects on the positive aspects of fibroblast activation.

Another factor to be considered is the myofibroblast origin. In recent years, there has been greater appreciation for the 3 different potential origins for the myofibroblasts in the remodeling process. These sources are: a) the resident interstitial fibroblast that undergoes transformation (Dewald, et al. 2004, Virag and Murry 2003, Yano, et al. 2005); b) the circulating precursor cells of bone marrow origin or fibrocytes that undergo differentiation (Haudek, et al. 2006, Keeley, et al. 2009, van Amerongen, et al. 2008); and c) the endothelial-mesenchymal transition (EndMT) originated cells (Zeisberg, et al. 2007). Of these three sources, recruitment of the resident interstitial fibroblast is thought to be the major source, although no studies have counted cells from the different sources in the post-MI setting. Whether myofibroblasts of different origin have similar or distinct roles in scar formation is still unclear and may be injury or tissue specific (Hertig, et al. 2009, Keeley, et al. 2009). Resident fibroblasts can become α smooth muscle actin (α SMA) positive cells and

produce increased ECM proteins upon activation by various cytokines and growth factors as numerous demonstrated in models of wound healing in skin and *in vitro* cardiac fibroblast studies (Weber 1997). One interesting concept to consider is that when normal resident fibroblasts are isolated and stimulated *in vitro*, in an attempt to gain mechanistic insight into fibroblast roles, are we missing potential differences because we are not evaluating fibroblasts from the other two origins?

In heart injury models, fibrocytes have been found expressing collagen and α SMA (Haudek, et al. 2006, van Amerongen, et al. 2008). In contrast, Yano and colleagues propose that proliferating myofibroblasts are derived solely from resident fibroblasts (Yano, et al. 2005). This discrepancy raises important questions: what factors stimulate the migration of bone marrow-derived cells into the injured tissue and what factors influence subsequent fibrocyte-derived fibroblast function? The presence of T lymphocytes may be an important element for the recruitment and differentiation of fibrocytes (van Amerongen, et al. 2008, Yano, et al. 2005). Caution needs to be taken on mechanisms of activation and function of the fibrocytes, however, as it has been shown that fibrocytes in the kidney do not produce collagen during renal fibrosis (Roufosse, et al. 2006). In lung fibrosis, on the other hand, collagen I α 1 is used as a fibrocyte marker. The exact role for fibrocytes in the LV response to MI remains to be fully elucidated to clarify these paradoxical results.

Another potential origin for myofibroblasts is cells undergoing EndMT, although this source may be relevant predominantly during embryogenesis (Goumans, et al. 2008). In a model of aortic banding, EndMT is promoted by TGF β and prevented by bone morphogenetic protein-7, as demonstrated by the presence of cells expressing markers of endothelial and mesenchymal cells but also α SMA (Zeisberg, et al. 2007).

After repair, myofibroblasts need to regress by an apoptotic mechanism in association with the completion of necrotic tissue replacement with fibrotic scar (Takemura, et al. 1998). Myofibroblasts have been observed in human hearts as late as 17 years after the MI, and fibroblasts numbers at the chronic stage reflect a state of sustained activation (Frantz, et al. 2009, Porter and Turner 2009). Persistent fibroblast activation is deleterious and promotes adverse remodeling that can transition to congestive heart failure.

3. Collagen is a critical component of the infarct scar

Cardiac ECM is composed of fibrous proteins, such as collagen and elastin that serve as steel reinforcements for the myocardium. ECM is composed of two types of glycosaminoglycans (GAGs), glycoproteins and proteoglycans, which serve as the space filling concrete. The exact ECM composition of the heart varies with age and physiological status.

Combined, collagens are an abundant family and have been calculated to account for up to 33% of the total protein in a tissue. Collagen is a glycoprotein, with 10% of weight being composed of carbohydrate. While collagen is a family of more than 25 distinct proteins, collagen I is the major fibrillar collagen in the heart (Carver, et al. 1993). For collagen I, three α chains generate a rope-like collagen that has a stiff, helical structure. Collagen synthesis is under the regulation of multiple transcription factors (Ghosh and Varga 2007, Kypriotou, et al. 2007). For example, the collagen I α 2 gene is regulated in cardiac fibroblasts by the transcription factor scleraxis (Espira, et al. 2009, Espira and Michael 2009). Collagen I is processed in the endoplasmic reticulum and golgi apparatus, where it is glycosylated, hydroxylated on selected proline and lysine residues, and the 3 α chains are covalently linked by disulfide-bonds. The 3 chains twist together to form a left-handed triple helix. A unique feature of collagen is the repeating basic unit Gly-X-Y, where X is frequently proline and Y is frequently hydroxyproline. Glycine and proline residues are

important for the triple-stranded helix conformation. Glycine is the smallest amino acid and allows the α chains to pack together tightly, while the proline ring structure stabilizes the left-handed helical conformation in each α chain. Because of the unique repeating unit, collagen levels are often measured by determining hydroxyproline levels (Bishop and Laurent 1995, Krane 2008). While this method offers quantitative information on total collagen levels, it does not provide qualitative information regarding subtype contributions or information on full length versus degraded forms as would be obtained by immunoblotting with specific collagen antibodies.

Secreted as pro-chains containing N and C terminal globular domains that keep collagen soluble, collagen is processed extracellularly to form collagen fibers. Hsp47 serves as a molecular chaperone during processing and secretion of pro-collagen and is a marker of collagen synthesis that increases in the post-MI setting (Sauk, et al. 2005, Takeda, et al. 2000). Collagen fibers are then assembled into fibrils, following by covalent crosslinking within and between lysine residues to crosslink fibrils. Matricellular proteins help collagen fibrils incorporate into the ECM, and ascorbic acid (vitamin C) is a required co-factor for prolyl hydroxylase, the enzyme that post-translationally modifies proline to hydroxyproline. Therefore, a lack of vitamin C in the diet can cause scurvy due abnormal collagen formation.

In the normal heart, collagen I is the major collagen type, and collagen I and III account for 90% of the total collagen (Carver, et al. 1993). Post-MI, collagen covers 30% of the infarct area at day 7 and 60% of the area at day 21 (Lindsey, et al. 2003). It is important to note, however, that in addition to collagen I, more than 24 other collagen types have been reported (Espira and Michael 2009). Post-MI, increases in collagen I, III, IV, V, and VI have been described. While cardiac fibroblasts are the predominant source of collagens, macrophages are also a source of collagen VI, highlighting a diverse function for this inflammatory cell (Schnoor, et al. 2008). The Meszaros laboratory wrote an excellent review on the non-fibrillar collagens, particularly collagen IV, V, and VI, and their roles post-MI (Shamhart and Meszaros 2010). However, there is not a lot of literature on other collagen types beyond these five, particularly in cardiovascular research. We know that collagen XVIII is anti-angiogenic when processed by MMPs to form endostatin (Wenzel, et al. 2006), but this area is ripe for investigation.

4. Collagen is not the only relevant ECM component

While collagen is the most studied ECM protein in the post-MI LV, it is not the only relevant ECM component that regulates MI wound healing. The fact that cardiac ECM is composed of varied proteins explains the structural and functional adaptability but also provides additional important regulators of scar formation (Espira and Michael 2009). In particular, laminin, fibronectin, thrombospondin, and tenascin are glycoproteins that have critical roles in post-MI remodeling. One interesting idea that has recently emerged is that ECM in the post-MI setting may recapitulate the timing and sequence (but not quantities) of ECM formation and deposition seen during development. If this is true, then time course data on ECM protein sequence may provide clues into how scar formation is coordinated.

Laminin is the first ECM glycoprotein seen in the developing embryo and may be a key coordinator of subsequent ECM formation (Espira and Michael 2009). Composed of 3 peptide chains (α , β , and γ) cross-linked by disulfide bonds, laminin is found in basement membrane but is not exclusively a basement membrane protein. Involved in cell-matrix interactions, laminin functions by anchoring cells to ECM and has binding sites for collagen IV, heparin, heparan sulfate, entactin, and laminin receptors (Suzuki, et al. 2005). Laminin helps maintain tissue organization, crosslinks other ECM, and serves as a very fine molecular sieve. In a rat post-MI model, laminin protein is seen by immunohistochemistry

beginning at day 3 post-MI (Morishita, et al. 1996). Laminin levels gradually increase to peak at about days 7–11 and return towards baseline thereafter. This pattern follows precisely the expression of collagen IV in the infarct. Laminin is processed by several matrix metalloproteinases, including MMP-9. Laminin peptides have been shown to be chemotactic for neutrophils (Adair-Kirk and Senior 2008, Mydel, et al. 2008) and to further induce MMP levels (Adair-Kirk, et al. 2003). Laminin, accordingly, coordinates multiple levels of the post-MI response.

Fibronectin is composed of type I, II, and III repeats that vary from monomer to monomer due to differential splicing of fibronectin mRNA, and more than 20 different monomer variants have been identified to date (White, et al. 2008). Formed from 2 subunits of approximately 250 kD each, fibronectin subunits are disulfide-bonded at the C-terminal regions. The cell-binding domain contains the arginine-glycine-aspartic acid (RGD) sequence essential for cell interactions between integrins and the RGD site. Fibronectin also has heparin and collagen binding sites and is soluble in blood but insoluble in the ECM. Fibronectin crosslinks and stabilizes other ECM components, and regulates cell shape and cell movement. For example, macrophages are guided into cardiac wound area by fibronectin, and soluble fibronectin crosslinks platelets and facilitates blood clotting (Frangogiannis 2006, Trial, et al. 2004). Fibronectin is involved in mechanotransduction and cell-matrix relationships, and has been shown to increase dramatically in the post-MI setting (Ulrich, et al. 1997). We have recently shown using a proteomics approach that fibronectin is an *in vivo* substrate of MMP-7 and MMP-9 in the LV infarct (Chiao, et al. 2010, Zamilpa, et al. 2010). Fibronectin fragments stimulate monocyte migration (Trial, et al. 1999) and increase MMP production (Schedin, et al. 2000), setting up a positive feedback loop in the remodeling myocardium. At the same time, macrophages stimulated with the 120 kD fibronectin fragments prevent apoptosis in injured cardiac myocytes, indicating that the same ECM fragment generated in the post-MI setting can have both positive and negative functions (Trial, et al. 2004).

Matricellular proteins do not directly contribute to ECM structure, but rather serve as accessory proteins to regulate cell-ECM interactions and help ECM to deposit properly. Matricellular proteins include the secreted protein acidic and rich in cysteine (SPARC), hevin, thrombospondins 1 and 2, tenascins C and X, periostin, all members of the CCN family, and osteopontin (McCurdy, et al. 2010). The CCN family was named after the first 3 members identified: cysteine-rich protein 61, connective tissue growth factor, and nephroblastoma overexpressed gene. SPARC binds collagens I, III, IV, and V and regulates the assembly of ECM containing these proteins. SPARC levels are high during cardiac development and are reexpressed following MI, consistent with a role in scar formation (McCurdy, et al. 2010, Schellings, et al. 2009, Wu, et al. 2006). The absence of SPARC results in ECM that is disarrayed in terms of structure and composition (Bradshaw, et al. 2003). In a pressure-overload model, the Bradshaw team has shown that SPARC deletion results in a blunted fibrotic response, resulting in decreased levels of insoluble collagen and increased levels of soluble collagen that decreased LV stiffness (Bradshaw, et al. 2009).

Thrombospondin-1 (TSP-1) is a matricellular protein with angiostatic properties (Frangogiannis 2008). TSP-1 can activate TGF β by disrupting non-covalent interactions between TGF β and the latency associated peptide. Following MI, TSP-1 is markedly upregulated at the border zone, and the Frangogiannis laboratory has speculated that TSP-1 may serve as a barrier to prevent or limit infarct expansion and to protect the remote region from macrophage infiltration and myofibroblast activation (Frangogiannis 2008). As evidence for this theory, TSP-1 null mice show sustained increases in several chemokines (monocyte chemoattractant protein-1, macrophage inflammatory protein-1 α , and CXCL-10) and several cytokines (interleukin-1 β , interleukin-6, and TGF β), which suggests that TSP-1 may

help to curtail the inflammatory response (Chatila, et al. 2007, Frangogiannis, et al. 2005). Consistent with this, TSP-1 null mice show increased macrophage and myofibroblast densities.

Tenascins are ECM glycoproteins with high bioactivity (Brellier, et al. 2009). Tenascins support tissue structure and regulate cell fates. Among the members of the tenascin family protein, tenascin-C (TN-C) is expressed early post-MI at the interface between infarcts and intact myocardium (Willems, et al. 1996). TN-C modulates cardiomyocytes adhesion to the newly synthesized ECM and regulates myofibroblast recruitment (Imanaka-Yoshida, et al. 2001, Tamaoki, et al. 2005). While adhesion proteins, such as TN-C, are necessary at the early stage of repair, prolonged expression is detrimental. High serum level of TN-C in patients associates with a greater incidence of excessive remodeling and poor prognosis (Fujimoto, et al. 2009). This association data were confirmed in a cause and effect mouse MI model, as TN-C deficient mice presented reduced interstitial fibrosis post-MI (Nishioka, et al. 2010).

Biglycan is a small leucine-rich proteoglycan that has been shown to increase post-MI in rats, mice, and humans (Doi, et al. 2000, Tiede, et al. 2010, Westermann, et al. 2008). Biglycan levels increase at day 2 and peak at day 14 in the rat (Doi, et al. 2000). Biglycan binds collagen fibrils and modulates fibril diameter and lateral fusion with other fibrils, which increases collagen network stability (Yamamoto, et al. 1998). Biglycan association with collagen also renders collagen less susceptible to proteolytic digestion. Biglycan inhibits TGF β activity, while TGF β stimulates biglycan production in cardiac fibroblasts. Biglycan stimulates macrophage activation through interactions with Toll-like receptors 2 and 4 (Schaefer, et al. 2005). Biglycan deficient mice show increased post-MI rupture, consistent with its crucial role in collagen deposition.

Decorin is a small dermatan sulfate proteoglycan that has been shown in the rat to increase at day 7 post-MI and peak on day 14, with fibroblasts being the primary cell source (Doi, et al. 2000). MMP-2, -3, and -7 can degrade decorin *in vitro* (Imai, et al. 1997), and decorin matricryptins have been shown to inhibit angiogenesis (Sulochana, et al. 2005). Decorin null mice show abnormal scar tissue formation post-MI (Weis, et al. 2005).

Perlecan is another proteoglycan; specifically it is a heparan sulfate proteoglycan found in basement membranes. Perlecan synthesis increases in mouse cardiac fibroblasts post-MI (Nakahama, et al. 2000). Perlecan null mice are embryonic lethal due to cardiac defects, which precludes examining effects of perlecan deletion using this deletion strategy in the post-MI setting (Sasse, et al. 2008).

Hyaluronic acid is the simplest glycosaminoglycan, composed of regular repeating sequences of nonsulfated disaccharide units. The only glycosaminoglycan that does not contain sulfated sugars, hyaluronic acid attracts water to swell the ECM, which may be an important mechanism to facilitate cell migration during tissue injury. Hyaluronan accumulates in the post-MI LV, peaking at day 3 post-MI in the rat (Waldenstrom, et al. 1991). Hyaluronan also increases during inflammatory conditions such as sarcoidosis, idiopathic pulmonary fibrosis, and bleomycin-induced lung injury models. The hyaluronan receptor, CD44, regulates both the inflammatory and fibrotic responses to MI (Huebener, et al. 2008). Together, these studies indicate that hyaluronan may serve to increase tissue edema and increase presentation of ligands for inflammatory cell receptors (Gerdin and Hallgren 1997, Waldenstrom, et al. 1991).

5. Collagen I does not always equal collagen I

During the remodeling process, collagen I is cleaved by matrix metalloproteinases (e.g., MMP-1, -8, -9, -13, and -14) and other proteases to generate 75 and 25 kD collagen fragments (Krane 1982, Krane, et al. 1996, Wu, et al. 1990). Additional proteinases can then break collagen into further peptide fragments. In the 1990's, several teams including the Davis laboratory, showed that collagen fragments are biologically active. Termed matricryptins or matrikines, these fragments have been shown to regulate angiogenic, inflammatory, and fibrotic responses (Davis 2010). Other ECM components, including fibronectin, thrombospondin-1, laminin, tenascin C, decorin, and elastin have also been shown to generate matricryptins (Tran, et al. 2004, Tran, et al. 2005). Therefore, measuring collagen at the gene level or only by total hydroxyproline levels will not provide information on matricryptin generation as would be obtained by immunoblotting or proteomic techniques. Considering ECM quality, in addition to quantity, will provide a necessary additional level of information for the LV remodeling field.

6. ECM turnover following myocardial infarction is a balance between synthesis and degradation

ECM degradation is regulated by a multitude of proteases (Table 3). Of these, the serine proteases and matrix metalloproteinases (MMPs) are the best studied (Liaw and Crawford 1999, Singh, et al. 2004). MMP-1, for example, was first identified in 1962 by Gross and Lapiere, who described the breakdown of collagen in the metamorphosing tadpole tail (Gross and Lapiere 1962). MMPs process at least one ECM component *in vitro*, require calcium and zinc for full activity, and are inhibited in tissue by the tissue inhibitors of metalloproteinases (TIMPs) and in circulation by α_2 macroglobulin and other non-specific proteinase inhibitors. Because calcium is required for full MMP activity, calcium chelators (e.g., EDTA) are used *in vitro* to demonstrate MMP-specific activity (Tyagi, et al. 1993). Another *in vitro* inhibitor of MMP activity is 1,10 phenanthroline, which also inhibits by chelating the calcium and zinc (Dean, et al. 1985).

MMPs are synthesized as secreted or membrane bound forms. The secreted MMPs are released as a pro-enzyme, with activation occurring when approximately 10 kD is cleaved from the N-terminus. MMP-11 is an exception, as it is activated intracellularly by furin and secreted as an active enzyme (Santavica, et al. 1996). MMP activation occurs via the cysteine switch mechanism (Van Wart and Birkedal-Hansen 1990). During this process, the propeptide domain in the latent enzyme provides a cysteine that interacts with the Zn^{2+} in the active site and prevents enzyme activity. Pro-peptide cleavage dissociates the bond and exposes the active site. While the pro-domain contains a conserved sequence (PRCGVPDV) that is common to all 25 MMPs, the flanking sequence surrounding this domain is unique and MMP-specific (Park, et al. 1991). MMP activators include trypsin, plasmin, cathepsins, kallikrein, other MMPs, SH reactive agents, denaturants, and organomercurials (such as 4-aminophenylmercuric acetate). Interestingly, sodium dodecyl sulfate can activate MMPs by inducing a conformational change without cleaving the pro-domain, which explains why zymograms detect both latent and active MMPs (Makowski and Ramsby 1996). The MT-MMPs are exceptions to the activation process described above. MT-MMPs are cell surface receptors that retain their propeptide domain, which is required for TIMP binding and subsequent MMP activation (Cao, et al. 1998). MT1-MMP is a tightly regulated MMP-2 activator, whose mechanism has been worked out in great detail (Butler, et al. 1998, Itoh, et al. 1998, Kinoshita, et al. 1998, Pei and Weiss 1996).

In addition to (or as a result of) cleaving ECM components, MMP roles include regulation of cell migration and invasion; protein processing to activate or degrade the protein; cell

shedding of proteins; cell turnover; and activation of MMPs or MMP activators. The net effect of the MMP on cell function is determined by substrate availability. For example, MMPs can promote or inhibit cell growth, can regulate cell survival or cell death, and can influence angiogenesis in a positive or negative manner—all depending on which substrate is processed by the MMP (Sternlicht and Werb 2001). Recent investigations by the Schulz laboratory have shown that MMP-2 activation can occur intracellularly, resulting in cleavage of intracellular substrates such as contractile proteins such as troponin I and myosin light chain in cardiac myocytes (Ali and Schulz 2009, Kandasamy and Schulz 2009, Viappiani, et al. 2009). MMP-2 activation can be modulated by the presence of peroxynitrite and glutathione, which modifies the cysteine residue in the autoinhibitory domain (Viappiani, et al. 2009). During cardiac injury, oxidative stress levels increase, providing a source for the increased peroxynitrite and glutathione levels. The Schulz group has shown that glycogen synthase kinase-3 β can be processed at the N-terminus by MMP-2, resulting in the release of the inhibitory phosphorylated serine-9 to generate a truncated kinase that has increased activity (Kandasamy and Schulz 2009). MMP-7 has also been shown to have intracellular substrates, including connexin 43 that is cleaved at the intracellular C-terminal domain post-MI (Lindsey, et al. 2006). The revelations that MMPs have non-ECM substrates and that MMP can process intracellular substrates were two critical junctures in our quest to grasp the complexity of MMP biology. In the MI setting, for example, there are a wide array of cytokines and chemokines processed by MMP-9 (Table 4).

7. ECM remodeling in the post-MI setting is time and space dependent

At all stages post-MI, from the myocyte release of complement to initiate the inflammatory response to the fibrotic and angiogenic responses to transition to congestive heart failure, ECM remodeling is a continuum of progressive changes. Therefore, space and time considerations need to be kept in mind when evaluating data snapshots. For example, MMP-9 increases early post-MI and again during the transition to heart failure, but studies evaluating the in between phases may miss the importance of this particular MMP.

Another concept is the importance of looking at both the remote and infarct regions when examining post-MI tissue, as increases in either or both regions will provide functional clues. While an increase in MMP plasma levels is clinically more relevant than sampling tissue, this approach will not tell you where the increase is localized. Infarct tissue is highly active, such that mRNA levels are higher in the infarct compared to remote region, and the remote region is higher than control levels. Therefore, consideration should be given to both remote and infarct responses.

Where do we go from here?

Key areas that remain to be explored are shown in Table 5. The dynamics of ECM assembly, including the roles of matricellular accessory proteins, such as SPARC, thrombospondins, and tenascins, need to be better understood (McCurdy, et al., Poobalarahi, et al. 2006, Puolakkainen, et al. 2005, Tamaoki, et al. 2005). Downstream effects of matricryptin production likely play key roles, but little is known regarding which peptide may be clinically relevant for diagnostics or therapeutic intervention. Effects of co-morbidities, such as aging, diabetes, or the presence of systemic inflammation, are known to exacerbate LV response to MI. However, studies are still needed to delineate the mechanisms involved. Two methodologies that will help provide answers to these remaining questions include systems biology and proteomic approaches. Systems biology approaches that include complex computational methods using mathematical modeling are needed for us to better understand the LV response to MI on a global tissue level. Proteomic approaches will also inform us as to the pattern of global changes seen.

Comparative studies will also provide useful information. Comparisons across species will inform us on processes that are conserved across species and therefore, likely candidates for therapeutic interventions in humans (Dewald, et al. 2004). Comparisons across tissues (skin vs lung vs kidney vs heart) and how these tissues differentially (or similarly) respond to injury will provide information that has relevance to LV remodeling. Few studies incorporate multiple animal models in the experimental design or evaluate multiple tissue responses, in part due to time and cost issues.

In summary, we provide here an overview of cardiac ECM types present in post-MI LV and discuss how individual components contribute to cell and tissue level responses. Finally, we discussed key areas of research that may elucidate additional mechanisms and identify additional therapeutic options for the post-MI patient.

Acknowledgments

The authors acknowledge grant support from the Hawaii Community Foundation 20080485 (CJLS), NIH HL75360, the Veterans Administration, American Heart Association AHA 0855119F, and the Max and Minnie Tomerlin Voelcker Fund (MLL).

References

- Adair-Kirk TL, Atkinson JJ, Broekelmann TJ, Doi M, Tryggvason K, Miner JH, Mecham RP, Senior RM. A Site on Laminin {alpha}5, AQARSAASKVKVSMKF, Induces Inflammatory Cell Production of Matrix Metalloproteinase-9 and Chemotaxis. *J Immunol.* 2003; 171(1):398–406. [PubMed: 12817023]
- Adair-Kirk TL, Senior RM. Fragments of extracellular matrix as mediators of inflammation. *Int J Biochem Cell Biol.* 2008; 40(6-7):1101–1110. [PubMed: 18243041]
- Ali MA, Schulz R. Activation of MMP-2 as a key event in oxidative stress injury to the heart. *Front Biosci.* 2009; 14:699–716. [PubMed: 19273096]
- Banerjee I, Fuseler JW, Souders CA, Bowers SL, Baudino TA. The role of interleukin-6 in the formation of the coronary vasculature. *Microsc Microanal.* 2009; 15(5):415–421. [PubMed: 19709461]
- Bishop JE, Laurent GJ. Collagen turnover and its regulation in the normal and hypertrophying heart. *Eur Heart J* 16 Suppl C. 1995:38–44.
- Bowers SL, Borg TK, Baudino TA. The dynamics of fibroblast-myocyte-capillary interactions in the heart. *Ann N Y Acad Sci.* 2010; 1188:143–152. [PubMed: 20201897]
- Bradshaw AD, Baicu CF, Rentz TJ, Van Laer AO, Boggs J, Lacy JM, Zile MR. Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. *Circulation.* 2009; 119(2):269–280. [PubMed: 19118257]
- Bradshaw AD, Puolakkainen P, Dasgupta J, Davidson JM, Wight TN, Helene Sage E. SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. *J Invest Dermatol.* 2003; 120(6):949–955. [PubMed: 12787119]
- Brellier F, Tucker RP, Chiquet-Ehrismann R. Tenascins and their implications in diseases and tissue mechanics. *Scand J Med Sci Sports.* 2009; 19(4):511–519. [PubMed: 19422658]
- Brown RD, Ambler SK, Mitchell MD, Long CS. The Cardiac Fibroblast: Therapeutic Target in Myocardial Remodeling and Failure. *Annual Review of Pharmacology and Toxicology.* 2005; 45(1):657–687.
- Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, van Westrum SS, Crabbe T, Clements J, d'Ortho M-P, Murphy G. The TIMP2 Membrane Type 1 Metalloproteinase “Receptor” Regulates the Concentration and Efficient Activation of Progelatinase A. *J of Biological Chemistry.* 1998; 273(2):871–880.
- Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. *Cardiovasc Res.* 2005; 65(1):40–51. [PubMed: 15621032]

- Cao J, Drews M, Lee HM, Conner C, Bahou WF, Zucker S. The Propeptide Domain of Membrane Type 1 Matrix Metalloproteinase Is Required for Binding of Tissue Inhibitor of Metalloproteinases and for Activation of Pro-gelatinase A. *J Biol Chem*. 1998; 273(52):34745–34752. [PubMed: 9856998]
- Carver W, Terracio L, Borg TK. Expression and accumulation of interstitial collagen in the neonatal rat heart. *Anat Rec*. 1993; 236(3):511–520. [PubMed: 8363055]
- Chatelain P, Latour JG, Tran D, de Lorgeril M, Dupras G, Bourassa M. Neutrophil accumulation in experimental myocardial infarcts: relation with extent of injury and effect of reperfusion. *Circulation*. 1987; 75(5):1083–1090. [PubMed: 3568308]
- Chatila K, Ren G, Xia Y, Huebener P, Bujak M, Frangogiannis NG. The role of the thrombospondins in healing myocardial infarcts. *Cardiovasc Hematol Agents Med Chem*. 2007; 5(1):21–27. [PubMed: 17266545]
- Chiao YA, Zamilpa R, Lopez EF, Dai Q, Escobar GP, Hakala KW, Weintraub ST, Lindsey ML. In vivo Matrix Metalloproteinase-7 Substrates Identified in the Left Ventricle Post-Myocardial Infarction Using Proteomics. *J Proteome Res*. 2010
- Davis GE. Matricryptic sites control tissue injury responses in the cardiovascular system: relationships to pattern recognition receptor regulated events. *J Mol Cell Cardiol*. 2010; 48(3):454–460. [PubMed: 19751741]
- Dean DD, Muniz OE, Berman I, Pita JC, Carreno MR, Woessner JF Jr. Howell DS. Localization of collagenase in the growth plate of rachitic rats. *J Clin Invest*. 1985; 76(2):716–722. [PubMed: 2993364]
- Desmouliere A, Chaponnier C, Gabbiani G. Tissue repair, contraction, and the myofibroblast. *Wound Repair Regen*. 2005; 13(1):7–12. [PubMed: 15659031]
- Deten A, Volz HC, Briest W, Zimmer HG. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. *Cardiovasc Res*. 2002; 55(2):329–340. [PubMed: 12123772]
- Dewald O, Ren G, Duerr GD, Zoerlein M, Klemm C, Gersch C, Tincey S, Michael LH, Entman ML, Frangogiannis NG. Of Mice and Dogs: Species-Specific Differences in the Inflammatory Response Following Myocardial Infarction. *Am J Pathol*. 2004; 164(2):665–677. [PubMed: 14742270]
- Dewald O, Ren G, Duerr GD, Zoerlein M, Klemm C, Gersch C, Tincey S, Michael LH, Entman ML, Frangogiannis NG. Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. *Am J Pathol*. 2004; 164(2):665–677. [PubMed: 14742270]
- Dobaczewski M, Frangogiannis NG. Chemokines and cardiac fibrosis. *Front Biosci (Schol Ed)*. 2009; 1:391–405. [PubMed: 19482709]
- Doi M, Kusachi S, Murakami T, Ninomiya Y, Murakami M, Nakahama M, Takeda K, Komatsubara I, Naito I, Tsuji T. Time-dependent changes of decorin in the infarct zone after experimentally induced myocardial infarction in rats: comparison with biglycan. *Pathol Res Pract*. 2000; 196(1):23–33. [PubMed: 10674269]
- Espira L, Lamoureux L, Jones SC, Gerard RD, Dixon IM, Czubyrt MP. The basic helix-loop-helix transcription factor scleraxis regulates fibroblast collagen synthesis. *J Mol Cell Cardiol*. 2009; 47(2):188–195. [PubMed: 19362560]
- Espira L, Michael PC. Emerging concepts in cardiac matrix biology. *Canadian journal of physiology and pharmacology*. 2009; 87(12):996–1008. [PubMed: 20029536]
- Frangogiannis NG. Targeting the inflammatory response in healing myocardial infarcts. *Curr Med Chem*. 2006; 13(16):1877–1893. [PubMed: 16842199]
- Frangogiannis NG. The immune system and cardiac repair. *Pharmacol Res*. 2008
- Frangogiannis NG.; Entman, ML. Role of Inflammation Following Myocardial Ischemia and Reperfusion. In: Becker, RC., editor. *The Textbook of Coronary Thrombosis and Thrombolysis*. Kluwer Academic Publishers; Norwell, MA: 1997. p. 569-584.
- Frangogiannis NG, Ren G, Dewald O, Zymek P, Haudek S, Koerting A. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. *Circulation*. 2005; 111(22):2935–2942. [PubMed: 15927970]

- Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. *Cardiovasc Res.* 2002; 53(1):31–47. [PubMed: 11744011]
- Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. *Cardiovasc Res.* 2009; 81(3):474–481. [PubMed: 18977766]
- Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, Lonning S, Ling H, Ertl G, Bauersachs J. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. *Basic Res Cardiol.* 2008; 103(5):485–492. [PubMed: 18651091]
- Fujimoto N, Onishi K, Sato A, Terasaki F, Tsukada B, Nozato T, Yamada T, Imanaka-Yoshida K, Yoshida T, Ito M, Hiroe M. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure. *J Card Fail.* 2009; 15(10):898–905. [PubMed: 19944367]
- Gerdin B, Hallgren R. Dynamic role of hyaluronan (HYA) in connective tissue activation and inflammation. *J Intern Med.* 1997; 242(1):49–55. [PubMed: 9260566]
- Ghosh AK, Varga J. The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. *J Cell Physiol.* 2007; 213(3):663–671. [PubMed: 17559085]
- Goumans MJ, van Zonneveld AJ, ten Dijke P. Transforming growth factor beta-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis? *Trends Cardiovasc Med.* 2008; 18(8):293–298. [PubMed: 19345316]
- Gross J, Lapiere CM. Collagenolytic Activity in Amphibian Tissues: A Tissue Culture Assay. *Proc Natl Acad Sci.* 1962; 48:1014–1022. [PubMed: 13902219]
- Haudek SB, Xia Y, Huebener P, Lee JM, Carlson S, Crawford JR, Pilling D, Gomer RH, Trial J, Frangogiannis NG, Entman ML. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. *Proc Natl Acad Sci U S A.* 2006; 103(48):18284–18289. [PubMed: 17114286]
- Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. *Am J Pathol.* 1995; 146(2):419–428. [PubMed: 7856752]
- Hertig A, Gangadhar T, Kalluri R. enal studies provide an insight into cardiac extracellular matrix remodeling during health and disease. *J Mol Cell Cardiol.* 2009
- Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. *Mol Biol Cell.* 2001; 12(9):2730–2741. [PubMed: 11553712]
- Hinz B, Mastrangelo D, Iselin CE, Chaponnier C, Gabbiani G. Mechanical tension controls granulation tissue contractile activity and myofibroblast differentiation. *Am J Pathol.* 2001; 159(3):1009–1020. [PubMed: 11549593]
- Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The Myofibroblast. One Function, Multiple Origins. *Am J Pathol.* 2007
- Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. *Annu Rev Pathol.* 2009; 4:435–459. [PubMed: 18954287]
- Holmes JW, Borg TK, Covell JW. Structure and mechanics of healing myocardial infarcts. *Annu Rev Biomed Eng.* 2005; 7:223–253. [PubMed: 16004571]
- Hori M, Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. *Cardiovasc Res.* 2009; 81(3):457–464. [PubMed: 19047340]
- Huebener P, Abou-Khamis T, Zymek P, Bujak M, Ying X, Chatila K, Haudek S, Thakker G, Frangogiannis NG. CD44 Is Critically Involved in Infarct Healing by Regulating the Inflammatory and Fibrotic Response. *J Immunol.* 2008; 180(4):2625–2633. [PubMed: 18250474]
- Ikeuchi M, Tsutsui H, Shiomi T, Matsusaka H, Matsushima S, Wen J, Kubota T, Takeshita A. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. *Cardiovasc Res.* 2004; 64(3):526–535. [PubMed: 15537506]
- Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-b1 release. *Biochem J.* 1997; 322:809–814. [PubMed: 9148753]
- Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, Sakakura T, Yoshida T. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. *Lab Invest.* 2001; 81(7):1015–1024. [PubMed: 11454990]

- Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, an A, Dawood F, Wen WH, Shou Z, Liu P. Tissue expression and immunolocalization of tumor necrosis factor- α in postinfarction dysfunctional myocardium. *Circulation*. 1999; 99(11):1492–1498. [PubMed: 10086975]
- Itoh Y, Ito A, Iwata K, Tanzawa K, Mori Y, Nagase H. Plasma Membrane-bound Tissue Inhibitor of Metalloproteinases (TIMP)-2 Specifically Inhibits Matrix Metalloproteinase 2 (Gelatinase A) Activated on the Cell Surface. *J of Biological Chemistry*. 1998; 273(38):24360–24367.
- Kandasamy AD, Schulz R. Glycogen synthase kinase-3 β is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts. *Cardiovasc Res*. 2009; 83(4):698–706. [PubMed: 19493954]
- Keeley EC, Mehrad B, Strieter RM. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of fibrotic disorders. *Thromb Haemost*. 2009; 101(4):613–618. [PubMed: 19350102]
- Kinoshita T, Sato H, Okada A, Ohuchi E, Imai K, Okada Y, Seiki M. TIMP-2 Promotes Activation of Progelatinase A by Membrane-type 1 Matrix Metalloproteinase Immobilized on Agarose Beads. *J of Biological Chemistry*. 1998; 273(26):16098–16103.
- Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. *Am J Manag Care*. 2009; 15(2 Suppl):S36–41. [PubMed: 19355807]
- Krane SM. Collagenases and Collagen Degradation. *J of Investigative Dermatology*. 1982; 79:83s–86s.
- Krane SM. The importance of proline residues in the structure, stability and susceptibility to proteolytic degradation of collagens. *Amino Acids*. 2008; 35(4):703–710. [PubMed: 18431533]
- Krane SM, Byrne H, Lemaitre V, Henriot P, Jeffrey JJ, Witter JP, Liu X, Wu H, Jaenisch R, Eeckhout Y. Different Collagenase Gene Products Have Different Roles in Degradation of Type I Collagen. *J of Biological Chemistry*. 1996; 271(45):28509–28515.
- Kypriotou M, Beauchef G, Chadjichristos C, Widom R, Renard E, Jimenez SA, Korn J, Maquart F-X, Oddos T, Von Stetten O, Pujol J-P, Galera P. Human Collagen Krox Up-regulates Type I Collagen Expression in Normal and Scleroderma Fibroblasts through Interaction with Sp1 and Sp3 Transcription Factors. *J Biol Chem*. 2007; 282(44):32000–32014. [PubMed: 17698844]
- Lambert JM, Lopez EF, Lindsey ML. Macrophage roles following myocardial infarction. *Int J Cardiol*. 2008; 130(2):147–158. [PubMed: 18656272]
- Liaw L, Crawford HC. Functions of the extracellular matrix and matrix degrading proteases during tumor progression. *Braz J Med Biol Res*. 1999; 32(7):805–812. [PubMed: 10454737]
- Lindsey M, Wedin K, Brown MD, Keller C, Evans AJ, Smolen J, Burns AR, Rossen RD, Michael L, Entman M. Matrix-Dependent Mechanism of Neutrophil-Mediated Release and Activation of Matrix Metalloproteinase 9 in Myocardial Ischemia/Reperfusion. *Circulation*. 2001; 103:2181–2187. [PubMed: 11331260]
- Lindsey ML, Escobar GP, Mukherjee R, Goshorn DK, Sheats NJ, Bruce JA, Mains IM, Hendrick JK, Hewett KW, Gourdie RG, Matrisian LM, Spinale FG. Matrix Metalloproteinase-7 Affects Connexin-43 Levels, Electrical Conduction, and Survival After Myocardial Infarction. *Circulation*. 2006; 113(25):2919–2928. [PubMed: 16769909]
- Lindsey ML, Yoshioka J, MacGillivray C, Muangman S, Gannon J, Verghese A, Aikawa M, Libby P, Krane SM, Lee RT. Effect of a Cleavage-Resistant Collagen Mutation on Left Ventricular Remodeling. *Circ Res*. 2003; 93(3):238–245. [PubMed: 12855673]
- Makowski GS, Ramsby ML. Calibrating Gelatin Zymograms with Human Gelatinase Standards. *Analytical Biochemistry*. 1996; 236(2):353–356. [PubMed: 8660517]
- McCurdy S, Baicu CF, Heymans S, Bradshaw AD. Cardiac extracellular matrix remodeling: Fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). *J Mol Cell Cardiol*. In Press, Corrected Proof.
- McCurdy S, Baicu CF, Heymans S, Bradshaw AD. Cardiac extracellular matrix remodeling: fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). *J Mol Cell Cardiol*. 2010; 48(3):544–549. [PubMed: 19577572]
- Meier L, Hay ED. Stimulation of corneal differentiation by interaction between cell surface and extracellular matrix. I. Morphometric analysis of transfilter “induction”. *J Cell Biol*. 1975; 66(2):275–291. [PubMed: 1170178]

- Michael LH, Ballantyne CM, Zachariah JP, Gould KE, Pocius JS, Taffet GE, Hartley CJ, Pham TT, Daniel SL, Funk E, Entman ML. Myocardial infarction and remodeling in mice: effect of reperfusion. *Am J Physiol.* 1999; 277(2 Pt 2):H660–668. [PubMed: 10444492]
- Morishita N, Kusachi S, Yamasaki S, Kondo J, Tsuji T. Sequential changes in laminin and type IV collagen in the infarct zone--immunohistochemical study in rat myocardial infarction. *Jpn Circ J.* 1996; 60(2):108–114. [PubMed: 8683853]
- Mydel P, Shipley JM, Adair-Kirk TL, Kelley DG, Broekelmann TJ, Mecham RP, Senior RM. Neutrophil Elastase Cleaves Laminin-332 (Laminin-5) Generating Peptides That Are Chemotactic for Neutrophils. *J Biol Chem.* 2008; 283(15):9513–9522. [PubMed: 18178964]
- Nakahama M, Murakami T, Kusachi S, Naito I, Takeda K, Ohnishi H, Komatsubara I, Oka T, Ninomiya Y, Tsuji T. Expression of perlecan proteoglycan in the infarct zone of mouse myocardial infarction. *J Mol Cell Cardiol.* 2000; 32(6):1087–1100. [PubMed: 10888260]
- Nishioka T, Onishi K, Shimojo N, Nagano Y, Matsusaka H, Ikeuchi M, Ide T, Tsutsui H, Hiroe M, Yoshida T, Imanaka-Yoshida K. Tenascin-C may aggravate left ventricular remodeling and function after myocardial infarction in mice. *Am J Physiol Heart Circ Physiol.* 2010
- Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Cytokine Gene Expression After Myocardial Infarction in Rat Hearts: Possible Implication in Left Ventricular Remodeling. *Circulation.* 1998; 98(2):149–156. [PubMed: 9679721]
- Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA, Bourcier T. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. *Circulation.* 2004; 109(6):784–789. [PubMed: 14970116]
- Palatinus JA, Rhett JM, Gourdie RG. Translational lessons from scarless healing of cutaneous wounds and regenerative repair of the myocardium. *J Mol Cell Cardiol.* 2010; 48(3):550–557. [PubMed: 19560469]
- Park AJ, Matrisian LM, Kells AF, Pearson R, Yuan ZY, Navre M. Mutational analysis of the transin (rat stromelysin) autoinhibitor region demonstrates a role for residues surrounding the “cysteine switch”. *J Biol Chem.* 1991; 266(3):1584–1590. [PubMed: 1988438]
- Pei D, Weiss SJ. Transmembrane-deletion Mutants of the Membrane-type Matrix Metalloproteinase-1 Process Progelatinase A and Express Intrinsic Matrix-degrading Activity. *J of Biological Chemistry.* 1996; 271(15):9135–9140.
- Poobalarahi F, Baicu CF, Bradshaw AD. Cardiac myofibroblasts differentiated in 3D culture exhibit distinct changes in collagen I production, processing, and matrix deposition. *Am J Physiol Heart Circ Physiol.* 2006; 291(6):H2924–2932. [PubMed: 16891407]
- Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. *Pharmacol Ther.* 2009; 123(2):255–278. [PubMed: 19460403]
- Porter KE, Turner NA, O'Regan DJ, Ball SG. Tumor necrosis factor [alpha] induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. *Cardiovasc Res.* 2004; 64(3):507–515. [PubMed: 15537504]
- Puolakkainen PA, Bradshaw AD, Brekken RA, Reed MJ, Kyriakides T, Funk SE, Gooden MD, Vernon RB, Wight TN, Bornstein P, Sage EH. SPARC-thrombospondin-2-double-null mice exhibit enhanced cutaneous wound healing and increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges. *J Histochem Cytochem.* 2005; 53(5):571–581. [PubMed: 15872050]
- Riad A, Jager S, Sobirey M, Escher F, Yaulema-Riss A, Westermann D, Karatas A, Heimesaat MM, Bereswill S, Dragun D, Pauschinger M, Schultheiss HP, Tschope C. Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. *J Immunol.* 2008; 180(10):6954–6961. [PubMed: 18453617]
- Rossen RD, Michael LH, Kagiya A, Savage HE, Hanson G, Reisberg MA, Moake JN, Kim SH, Self D, Weakley S. Mechanism of complement activation after coronary artery occlusion: evidence that myocardial ischemia in dogs causes release of constituents of myocardial subcellular origin that complex with human C1q in vivo. *Circ Res.* 62:572–584. [PubMed: 3257722]
- Roufosse C, Bou-Gharios G, Prodromidi E, Alexakis C, Jeffery R, Khan S, Otto WR, Alter J, Poulosom R, Cook HT. Bone marrow-derived cells do not contribute significantly to collagen I synthesis in a murine model of renal fibrosis. *J Am Soc Nephrol.* 2006; 17(3):775–782. [PubMed: 16467445]

- Santavicca M, Noel A, Angliker H, Stoll I, Segain JP, Anglard P, Chretien M, Seidah N, Basset P. Characterization of structural determinants and molecular mechanisms involved in prostromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases. *Biochem J.* 1996; 315(Pt 3):953–958. [PubMed: 8645182]
- Sasse P, Malan D, Fleischmann M, Roell W, Gustafsson E, Bostani T, Fan Y, Kolbe T, Breitbach M, Addicks K, Welz A, Brem G, Hescheler J, Aszodi A, Costell M, Bloch W, Fleischmann BK. Perlecan is critical for heart stability. *Cardiovasc Res.* 2008; 80(3):435–444. [PubMed: 18694874]
- Sauk JJ, Nikitakis N, Siavash H. Hsp47 a novel collagen binding serpin chaperone, autoantigen and therapeutic target. *Front Biosci.* 2005; 10:107–118. [PubMed: 15574354]
- Schaefer L, Babelova A, Kiss E, Hausser H-J, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Gotte M, Malle E, Schaefer RM, Grone H-J. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. *J. Clin. Invest.* 2005; 115(8):2223–2233. [PubMed: 16025156]
- Schedin P, Strange R, Mitrenga T, Wolfe P, Kaeck M. Fibronectin fragments induce MMP activity in mouse mammary epithelial cells: evidence for a role in mammary tissue remodeling. *J Cell Sci.* 2000; 113(5):795–806. [PubMed: 10671369]
- Schellings MW, Vanhoutte D, Swinnen M, Cleutjens JP, Debets J, van Leeuwen RE, d'Hooge J, Van de Werf F, Carmeliet P, Pinto YM, Sage EH, Heymans S. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. *J Exp Med.* 2009; 206(1):113–123. [PubMed: 19103879]
- Schnoor M, Cullen P, Lorkowski J, Stolle K, Robenek H, Troyer D, Rauterberg J, Lorkowski S. Production of Type VI Collagen by Human Macrophages: A New Dimension in Macrophage Functional Heterogeneity. *J Immunol.* 2008; 180(8):5707–5719. [PubMed: 18390756]
- Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, Gabbiani G. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. *J Cell Biol.* 1998; 142(3):873–881. [PubMed: 9700173]
- Serini G, Gabbiani G. Mechanisms of myofibroblast activity and phenotypic modulation. *Exp Cell Res.* 1999; 250(2):273–283. [PubMed: 10413583]
- Shamhart PE, Meszaros JG. Non-fibrillar collagens: key mediators of post-infarction cardiac remodeling? *J Mol Cell Cardiol.* 2010; 48(3):530–537. [PubMed: 19573533]
- Shimazaki M, Nakamura K, Kii I, Kashima T, Amizuka N, Li M, Saito M, Fukuda K, Nishiyama T, Kitajima S, Saga Y, Fukayama M, Sata M, Kudo A. Periostin is essential for cardiac healing after acute myocardial infarction. *J. Exp. Med.* 2008; 205(2):295–303. [PubMed: 18208976]
- Singh RB, Dandekar SP, Elimban V, Guptak SK, Dhalla NS. Role of proteases in the pathophysiology of cardiac disease. *Mol Cell Biochem.* 2004; 263:241–256. [PubMed: 15524184]
- Sternlicht M, Werb Z. How Matrix Metalloproteinases Regulate Cell Behavior *Annu Rev Cell Dev Biol.* 2001; 17(1):463–516.
- Stutz A, Golenbock DT, Latz E. Inflammasomes: too big to miss. *J Clin Invest.* 2009; 119(12):3502–3511. [PubMed: 19955661]
- Sulochana KN, Fan H, Jois S, Subramanian V, Sun F, Kini RM, Ge R. Peptides Derived from Human Decorin Leucine-rich Repeat 5 Inhibit Angiogenesis. *J. Biol. Chem.* 2005; 280(30):27935–27948. [PubMed: 15923192]
- Sun Y, Zhang JQ, Zhang J, Lamparter S. Cardiac remodeling by fibrous tissue after infarction in rats. *Journal of Laboratory and Clinical Medicine.* 2000; 135(4):316–323. [PubMed: 10779047]
- Suzuki N, Yokoyama F, Nomizu M. Functional sites in the laminin alpha chains. *Connect Tissue Res.* 2005; 46(3):142–152. [PubMed: 16147852]
- Takeda K, Kusachi S, Ohnishi H, Nakahama M, Murakami M, Komatsubara I, Oka T, Doi M, Ninomiya Y, Tsuji T. Greater than normal expression of the collagen-binding stress protein heat-shock protein-47 in the infarct zone in rats after experimentally-induced myocardial infarction. *Coron Artery Dis.* 2000; 11(1):57–68. [PubMed: 10715808]
- Takemura G, Ohno M, Hayakawa Y, Misao J, Kanoh M, Ohno A, Uno Y, Minatoguchi S, Fujiwara T, Fujiwara H. Role of Apoptosis in the Disappearance of Infiltrated and Proliferated Interstitial Cells After Myocardial Infarction. *Circulation. Res.* 1998; 82:1130–1138. [PubMed: 9633913]

- Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, Sakakura T, Yoshida T. Tenascin-C Regulates Recruitment of Myofibroblasts during Tissue Repair after Myocardial Injury. *Am J Pathol.* 2005; 167(1):71–80. [PubMed: 15972953]
- Tiede K, Melchior-Becker A, Fischer J. Transcriptional and posttranscriptional regulators of biglycan in cardiac fibroblasts. *Basic Research in Cardiology.* 2010; 105(1):99–108. [PubMed: 19701788]
- Tran KT, Griffith L, Wells A. Extracellular matrix signaling through growth factor receptors during wound healing. *Wound Repair Regen.* 2004; 12(3):262–268. [PubMed: 15225204]
- Tran KT, Lamb P, Deng JS. Matrikines and matricryptins: Implications for cutaneous cancers and skin repair. *J Dermatol Sci.* 2005; 40(1):11–20. [PubMed: 15993569]
- Trial J, Baughn RE, Wygant JN, McIntyre BW, Birdsall HH, Youker KA, Evans A, Entman ML, Rossen RD. Fibronectin fragments modulate monocyte VLA-5 expression and monocyte migration. *J Clin Invest.* 1999; 104(4):419–430. [PubMed: 10449434]
- Trial J, Rossen RD, Rubio J, Knowlton AA. Inflammation and Ischemia: Macrophages Activated by Fibronectin Fragments Enhance the Survival of Injured Cardiac Myocytes. *Experimental Biology and Medicine.* 2004; 229(6):538–545. [PubMed: 15169973]
- Turner NA, Das A, Warburton P, O'Regan DJ, Ball SG, Porter KE. Interleukin-1 α stimulates proinflammatory cytokine expression in human cardiac myofibroblasts. *Am J Physiol Heart Circ Physiol.* 2009; 297(3):H1117–1127. [PubMed: 19648252]
- Turner NA, Mughal RS, Warburton P, O'Regan DJ, Ball SG, Porter KE. Mechanism of TNF α -induced IL-1 α , IL-1 β and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. *Cardiovasc Res.* 2007; 76(1):81–90. [PubMed: 17612514]
- Turner NA, O'Regan DJ, Ball SG, Porter KE. Endothelin-1 is an essential co-factor for β 2-adrenergic receptor-induced proliferation of human cardiac fibroblasts. *FEBS Lett.* 2004; 576(1–2):156–160. [PubMed: 15474029]
- Tyagi SC, Matsubara L, Weber KT. Direct Extraction and Estimation of Collagenase(s) Activity by Zymography in Microquantities of Rat Myocardium and Uterus. *Clin Biochem.* 1993; 26:191–198. [PubMed: 8330388]
- Ulrich MM, Janssen AM, Daemen MJ, Rappaport L, Samuel JL, Contard F, Smits JF, Cleutjens JP. Increased expression of fibronectin isoforms after myocardial infarction in rats. *J Mol Cell Cardiol.* 1997; 29(9):2533–2543. [PubMed: 9299376]
- van Amerongen MJ, Bou-Gharios G, Popa E, van Ark J, Petersen AH, van Dam GM, van Luyn MJ, Harmsen MC. Bone marrow-derived myofibroblasts contribute functionally to scar formation after myocardial infarction. *J Pathol.* 2008; 214(3):377–386. [PubMed: 18095257]
- van den Borne SWM, van de Schans VAM, Strzelecka AE, Vervoort-Peters HTM, Lijnen PM, Cleutjens JPM, Smits JFM, Daemen MJAP, Janssen BJA, Blankesteijn WM. Mouse strain determines the outcome of wound healing after myocardial infarction. *Cardiovasc Res.* 2009; 84(2):273–282. [PubMed: 19542177]
- Van Wart HE, Birkedal-Hansen H. The cysteine switch: A principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. *Proc Natl Acad Sci USA.* 1990; 87(Biochemistry):5578–5582. [PubMed: 2164689]
- Vandervelde S, van Amerongen MJ, Tio RA, Petersen AH, van Luyn MJ, Harmsen MC. Increased inflammatory response and neovascularization in reperfused vs. non-reperfused murine myocardial infarction. *Cardiovasc Pathol.* 2006; 15(2):83–90. [PubMed: 16533696]
- Viappiani S, Nicolescu AC, Holt A, Sawicki G, Crawford BD, Leon H, an Mulligen T, Schulz R. Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. *Biochem Pharmacol.* 2009; 77(5):826–834. [PubMed: 19046943]
- Virag JI, Murry CE. Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair. *Am J Pathol.* 2003; 163(6):2433–2440. [PubMed: 14633615]
- Waldenstrom A, Martinussen HJ, Gerdin B, Hallgren R. Accumulation of hyaluronan and tissue edema in experimental myocardial infarction. *J Clin Invest.* 1991; 88(5):1622–1628. [PubMed: 1939649]
- Weber KT. Monitoring tissue repair and fibrosis from a distance. *Circulation.* 1997; 96(8):2488–2492. [PubMed: 9355880]

- Weis SM, Zimmerman SD, Shah M, Covell JW, Omens JH, Ross J, John, Dalton N, Jones Y, Reed CC. A role for decorin in the remodeling of myocardial infarction. *Matrix Biology*. 2005; 24(4): 313–324. [PubMed: 15949932]
- Wenzel D, Schmidt A, Reimann K, Hescheler J, Pfitzer G, Bloch W, Fleischmann BK. Endostatin, the Proteolytic Fragment of Collagen XVIII, Induces Vasorelaxation. *Circ Res*. 2006; 98(9):1203–1211. [PubMed: 16574906]
- Westermann D, Mersmann J, Melchior A, Freudenberger T, Petrik C, Schaefer L, Lullmann-Rauch R, Lettau O, Jacoby C, Schrader J, Brand-Herrman SM, Young MF, Schultheiss HP, Levkau B, Baba HA, Unger T, Zacharowski K, Tschope C, Fischer JW. Biglycan Is Required for Adaptive Remodeling After Myocardial Infarction. *Circulation*. 2008; 117(10):1269–1276. [PubMed: 18299507]
- White ES, Baralle FE, Muro AF. New insights into form and function of fibronectin splice variants. *J Pathol*. 2008; 216(1):1–14. [PubMed: 18680111]
- Willems IE, Arends JW, Daemen MJ. Tenascin and fibronectin expression in healing human myocardial scars. *J Pathol*. 1996; 179(3):321–325. [PubMed: 8774490]
- Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. *Mucosal Immunol*. 2009; 2(2):103–121. [PubMed: 19129758]
- Wu H, Byrne MH, Stacey A, Goldring MB, Birkhead JR, Jaenisch R, Krane SM. Generation of collagenase-resistant collagen by site-directed mutagenesis of murine pro α 1(I) collagen gene. *Proc Natl Acad Sci USA*. 1990; 87:5888–5892. [PubMed: 2165607]
- Wu RX, Laser M, Han H, Varadarajulu J, Schuh K, Hallhuber M, Hu K, Ertl G, Hauck CR, Ritter O. Fibroblast migration after myocardial infarction is regulated by transient SPARC expression. *Journal of Molecular Medicine*. 2006; 78(3):241–252. [PubMed: 16416312]
- Wynn TA. Cellular and molecular mechanisms of fibrosis. *J Pathol*. 2008; 214(2):199–210. [PubMed: 18161745]
- Yamamoto K, Kusachi S, Ninomiya Y, Murakami M, Doi M, Takeda K, Shinji T, Higashi T, Koide N, Tsuji T. Increase in the expression of biglycan mRNA expression Co-localized closely with that of type I collagen mRNA in the infarct zone after experimentally-induced myocardial infarction in rats. *J Mol Cell Cardiol*. 1998; 30(9):1749–1756. [PubMed: 9769230]
- Yano T, Miura T, Ikeda Y, Matsuda E, Saito K, Miki T, Kobayashi H, Nishino Y, Ohtani S, Shimamoto K. Intracardiac fibroblasts, but not bone marrow derived cells, are the origin of myofibroblasts in myocardial infarct repair. *Cardiovasc Pathol*. 2005; 14(5):241–246. [PubMed: 16168896]
- Zamilpa R, Lopez EF, Chiao YA, Dai Q, Escobar GP, Hakala K, Weintraub ST, Lindsey ML. Proteomic Analysis Identifies In vivo Candidate Matrix Metalloproteinase-9 Substrates in the Left Ventricle Post-Myocardial Infarction. *Proteomics*. 2010
- Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. *Nat Med*. 2007; 13(8):952–961. [PubMed: 17660828]
- Apostolakis S, Lip GYH, Shantsila E. Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair? *Cardiovasc Res*. 2010; 85(4):649–660. [PubMed: 19805399]
- Bujak M, Frangogiannis NG. The role of IL-1 in the pathogenesis of heart disease. *Arch Immunol Ther Exp (Warsz)*. 2009; 57(3):165–176. [PubMed: 19479203]
- Cauwe B, eacute, eacute, dicte, Steen PEVd, Opdenakker G. The Biochemical, Biological, and Pathological Kaleidoscope of Cell Surface Substrates Processed by Matrix Metalloproteinases. *Critical Reviews in Biochemistry and Molecular Biology*. 2007; 42(3):113–185. [PubMed: 17562450]
- Chintala SK, Zhang X, Austin JS, Fini ME. Deficiency in Matrix Metalloproteinase Gelatinase B (MMP-9) Protects against Retinal Ganglion Cell Death after Optic Nerve Ligation. *J. Biol. Chem*. 2002; 277(49):47461–47468. [PubMed: 12354772]

- Dobaczewski M, Bujak M, Zymek P, Ren G, Entman ML, Frangogiannis NG. Extracellular matrix remodeling in canine and mouse myocardial infarcts. *Cell and Tissue Research*. 2006; V324(3): 475–488. [PubMed: 16496177]
- Egeblad M, Werb Z. New Functions for the Matrix Metalloproteinases in Cancer Progression. *Nat Rev Cancer*. 2002; 2(3):163–176.
- Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis. *Basic Research in Cardiology*. 2007; 102(4):279–297. [PubMed: 17530315]
- Frangogiannis NG. The immune system and cardiac repair. *Pharmacol Res*. 2008
- Gearing AJH, Beckett P, Christodoulou M, Churchill M, Blements JM, Crimmin M, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Lebel TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Woolley K. Matrix metalloproteinases and processing of pro-TNF- α . *J Leukocyte Biol*. 1995; 57:774–777. [PubMed: 7759957]
- Gu Z, Cui J, Brown S, Fridman R, Mobashery S, Strongin AY, Lipton SA. A Highly Specific Inhibitor of Matrix Metalloproteinase-9 Rescues Laminin from Proteolysis and Neurons from Apoptosis in Transient Focal Cerebral Ischemia. *J. Neurosci*. 2005; 25(27):6401–6408. [PubMed: 16000631]
- Henning RJ, Shariff M, Eadula U, Alvarado F, Vasko M, Sanberg PR, Sanberg CD, Delostia V. Human Cord Blood Mononuclear Cells Decrease Cytokines and Inflammatory Cells in Acute Myocardial Infarction. *Stem Cells and Development*. 2008; 17(6):1207–1220. [PubMed: 18393684]
- Lindsey ML. Novel strategies to delineate matrix metalloproteinase (MMP)-substrate relationships and identify targets to block MMP activity. *Mini Rev Med Chem*. 2006; 6(11):1243–1248. [PubMed: 17100635]
- Marom B, Rahat MA, Lahat N, Weiss-Cerem L, Kinarty A, Bitterman H. Native and fragmented fibronectin oppositely modulate monocyte secretion of MMP-9. *J Leukoc Biol*. 2007; 81(6): 1466–1476. [PubMed: 17327485]
- McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! *Current Opinion in Cell Biology*. 2001; 13(5):534–540. [PubMed: 11544020]
- McCawley LJ, Matrisian LM. Tumor progression: defining the soil round the tumor seed. *Curr Biol*. 2001; 11(1):R25–27. [PubMed: 11166192]
- Morodomi T, Ogata Y, Sasaguri Y, Morimatsu M, Nagase H. Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. *Biochem J*. 1992; 285(Pt 2):603–611. [PubMed: 1379048]
- Sasaki T, Gohring W, Mann K, Maurer P, Hohenester E, Knauper V, Murphy G, Timpl R. Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. *J Biol Chem*. 1997; 272(14):9237–9243. [PubMed: 9083057]
- Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. *Oncogene*. 2007; 26(44):6361–6371. [PubMed: 17452979]
- Vaisar T, Kassim SY, Gomez IG, Green PS, Hargarten S, Gough PJ, Parks WC, Wilson CL, Raines EW, Heinecke JW. MMP-9 sheds the beta2 integrin subunit (CD18) from macrophages. *Mol Cell Proteomics*. 2009; 8(5):1044–1060. [PubMed: 19116209]

Figure 1.

During the MI response, cardiac fibroblasts are recruited from resting resident cells and from a pool of circulating fibrocytes and are stimulated to undergo phenotypic modulation to become myofibroblasts. Increased proliferation and increased ECM synthesis are prime characteristics of the cardiac fibroblasts within the infarct zone. If infarct wound healing occurs optimally, the fibroblast undergoes apoptosis to decrease numbers. Persistent fibroblast activation occurs during adverse remodeling that will progress to heart failure. Abbreviations: ACE- angiotensin converting enzyme; Aldo- aldosterone; Ang II- angiotensin II; β AR- β - adrenergic receptor; bFGF- basic fibroblast growth factor; CTP- C-terminal peptide; ET-1-endothelin-1; IFN γ - Interferon γ ; IL- interleukin; iNOS- inducible nitric oxide synthase; MCP-1-monocyte chemotactic protein-1; MMP- matrix metalloproteinase; ROS- reactive oxygen species; α SMA- α smooth muscle actin; TGF β - transforming growth factor β ; TIMP- tissue inhibitor of metalloproteinase; TNF α - tumor necrosis factor α ; VEGF- vascular endothelial growth factor.

Table 1

Myocardial ECM Proteins Upregulated Post-MI.(Dobaczewski, et al. 2006)

Collagen I, III, IV, V, and VI
Fibronectin
Fibullin
Hyaluronan
Laminins
Matrix Metalloproteinase
Osteopontin
Periostin
Secreted Protein Acidic and Rich in Cysteine
Tenascins
Thrombospondin -1and -2
Tissue Inhibitors of Metalloproteinase -1, -2, -3, and -4
Transforming Growth Factor β
Versican
Vitronectin

Table 2

Cytokines, chemokines, and growth factors that increase Post-MI.(Apostolakis, et al. 2010,Bujak and Frangogiannis 2009,Fischer and Hilfiker-Kleiner 2007,Frangogiannis 2008,Henning, et al. 2008)

Factor	Roles
Cardiotrophin-1	Stimulates LV hypertrophy and protects cardiomyocytes from apoptosis; stimulates cardiac fibroblast proliferation
Ciliary Neutrophilic Factor	IL-6 family member; anti-inflammatory
Epithelial cell-derived neutrophil-activating peptide -78 (CXCL5)	Neutrophil chemoattractants; angiogenic
Fractalkine (CX3CL1)	Neutrophil and monocyte chemoattractant; stimulates vascular oxygen free radicals
Granulocyte Colony Stimulating Factor	Prevents cardiomyocyte and endothelial cell apoptosis
Growth Related Oncogene $\alpha/\beta/\gamma$ (CXCL1/2/3)	Neutrophil chemoattractants; angiogenic
Interferon γ	Stimulates TNF α production and leukocyte migration; increases oxygen free radical production; activates MMPs
Interleukin-1 α/β	Upstream modulators of pro-inflammatory mediators; stimulates MMPs in cardiac fibroblasts
Interleukin-6	Upstream modulator of inflammation and fibrosis
Interleukin-8 (CXCL8)	Neutrophil activator; induces smooth muscle cell proliferation and migration; angiogenic
Interleukin-10	Stimulates anti-inflammatory pathways; inhibits NF- κ B; decreases macrophage activation
Interleukin-11	Stimulates atrial fibrillation and hypertrophy
Interleukin-12	Induces TNF α and IFN γ
Interleukin-17	Proinflammatory; induces fibroblasts, endothelial cells and macrophage to produce cytokines and chemokines
Interleukin-18	Induces IFN γ ; pro-inflammatory
Interferon γ inducible protein-10 (CXCL10)	Angiostatic
IFN-inducible T cell α (CXCL11)	Leukocyte recruitment, angiostatic
Leukemia Inhibitory Factor	Stimulates myocyte hypertrophy and survival; stimulates cardiac fibroblast proliferation, reduces collagen and MMP production, decreased conversion to myofibroblasts; in vivo, limits infarct size and induces neovascularization, and decrease fibrosis
Lipopolysaccharide-induced CXC (CXCL-5)	Leukocyte recruitment
Lymphotoxin (XCL1)	Lymphocyte recruitment
Monocyte Chemotactic Protein-1/-3/-5 (CCL2/7/12)	Monocyte chemoattractants; induces smooth muscle cell proliferation; angiogenic
Monokine Induced by Interferon γ (CXCL9)	Angiostatic
Macrophage Inflammatory Protein-1 α/β (CCL3/4)	Neutrophil activator; induces pro-inflammatory cytokines; monocyte chemoattractant
Neutrophil-Activating Peptide-2 (CXCL7)	Neutrophil chemoattractants; angiogenic
Oncostatin M	Protects myocytes and stimulated increased production of TIMP-1 and plasminogen activator inhibitor 1; stimulates endothelial cell MCP-1 expression, proliferation, and migration; induces cardiac fibroblast release of CXCL-1 and -5, cell survival, proliferation, and increased ECM synthesis
Platelet Factor-4 (CXCL-4)	Angiostatic; MMP-9 substrate
Regulated on Activation, Normal T Expressed and Secreted (CCL5)	Monocyte chemoattractant
Stromal Derived Factor-1 (CXCL-12)	Chemoattractant for CD34+ progenitor and primitive hematopoietic cells
Transforming Growth Factor β 1,2,3	Regulates the transition from inflammation to fibrosis

Factor	Roles
Tumor Necrosis Factor α	Effects all cell types in the post-MI LV; suppresses myocyte contractility and induces apoptosis; neutrophil chemoattractant; is pro-inflammatory; increases MMPs and decreases collagen synthesis in cardiac fibroblasts
Vascular Endothelial Growth Factor	Stimulates angiogenesis

Table 3

Proteases that regulate ECM turnover.

Protease	Type	Examples
Serine	Neutral	Elastase, Cathepsin G, Thrombin, Plasmin, Tryptase, Proteinase 3
Cysteine	Acidic	Cathepsin S, Cathepsin L, Cathepsin B
Aspartic	Acidic	Cathepsin D
Matrix Metalloproteinase	Neutral	MMP-1 to -3; -7 to -28

Table 4

ECM and Non-ECM Substrates Processed by MMP-9 (Cauwe, et al. 2007, Chintala, et al. 2002, Egeblad and Werb 2002, Gearing, et al. 1995, Gu, et al. 2005, Lindsey 2006, Marom, et al. 2007, McCawley and Matrisian 2001, McCawley and Matrisian 2001, Morodomi, et al. 1992, Sasaki, et al. 1997, Takafuji, et al. 2007, Vaisar, et al. 2009)

α 1 Proteinase Inhibitor
α 2 Macroglobulin
A disintegrin and metalloproteinase with thrombospondin motifs-4
CD 16, 18, 25, 27, 30, 31, 40L, 44, 54, 120, 163, 206
C-kit ligand
Collagen I, II, III, IV, V, VII, X, XI, XIV, XVIII
Complement C1q
Chemokine CXC Ligand-1, -4, -5, -6, -7, -8, -10, -12, -17
Desmocollin-3
Desmoglein-1, -3
β Dystroglycan
Elastin
Endothelin-1
Entactin
Fibrin
Fibrinogen
Fibroblast Growth Factor Receptor 1
Fibronectin
Galectin-3
Heparin-binding EGF-like growth factor
Heparan Sulfate Proteoglycans
Insulin-like Growth Factor Binding Protein-3
Interleukin-1 β (pro and active)
Interleukin receptors- 2 α , 6 α
Integrins- β ₂
Laminin
Latent TGF β binding protein
Macrophage colony-stimulating factor
MMP-2, -13
NG2 Proteoglycan
Nidogen
Occludin
Osteopontin
Plasminogen
Proteoglycans
Proteoglycans link protein
Stromal Cell-Derived Factor-1
Secreted Protein Acidic and Rich in Cysteine

Substance P
Syndecan-1, -3, -4
Tissue Factor Pathway Inhibitor
Thyrotropin Receptor
Tumor Necrosis Factor α (pro)
Tumor Necrosis Factor Receptors
Urokinase Plasminogen Activator Receptor-1

Table 5**Key Areas to Be Explored**

1	Dynamics of ECM assembly
2	Downstream effects of ECM turnover
3	Effects of co-morbidities
4	Systems biology approaches for multi-dimensional kinetic analysis
5	Comparative studies across species and tissue types
6	Driver vs passenger effects to assign cause and effect roles